Literature DB >> 3470055

Improved results of treatment of adult acute lymphoblastic leukemia.

C A Linker, L J Levitt, M O'Donnell, C A Ries, M P Link, S J Forman, M J Farbstein.   

Abstract

We designed a treatment program to improve the outcome for adults with acute lymphoblastic leukemia (ALL). Treatment included a remission-induction phase followed by intensive alternating cycles of non-cross-resistant chemotherapy and prolonged oral maintenance therapy. Eighty-one consecutive previously untreated patients were entered on this study. Ninety-four percent of patients entered complete remission. A Kaplan-Meier analysis predicts that 53% +/- 9% (SEM) of patients in remission will remain free of disease at 3 years. Neither age, sex, WBC count, nor immunophenotype had a significant effect on remission duration. This program of intensive cyclical chemotherapy has improved the disease-free survival of patients with adult ALL.

Entities:  

Mesh:

Year:  1987        PMID: 3470055

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

Review 1.  Biology and treatment of adult acute lymphoblastic leukemia.

Authors:  L Levitt; R Lin
Journal:  West J Med       Date:  1996-02

2.  Treatment of adult acute lymphoblastic leukaemia using an intensive chemotherapy protocol.

Authors:  R Liang; T K Chan; G T Chan; D Todd
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 3.  [Post-remission treatment of acute leukemia in adulthood: allogeneic bone marrow transplantation or chemotherapy?].

Authors:  U Jehn; R Grunewald
Journal:  Klin Wochenschr       Date:  1988-07-15

4.  Analysis of 20-year follow-up study of LVP regimen for adult acute lymphoblastic leukemia.

Authors:  Y Hatta; J Takeuchi; T Ohshima; A Horikoshi; Y Iizuka; M Kawamura; M Kanemaru; T Horie
Journal:  Int J Hematol       Date:  2001-08       Impact factor: 2.490

5.  Acute leukemia: diagnosis, management, and potential for cure.

Authors:  K Stewart; A Keating
Journal:  Can Fam Physician       Date:  1988-11       Impact factor: 3.275

6.  Rearrangements of the tal-1 locus as clonal markers for T cell acute lymphoblastic leukemia.

Authors:  O G Jonsson; R L Kitchens; R J Baer; G R Buchanan; R G Smith
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

7.  Nation-wide randomized comparative study of doxorubicin, vincristine and prednisolone combination therapy with and without L-asparaginase for adult acute lymphoblastic leukemia.

Authors:  E Nagura; K Kimura; K Yamada; K Ota; T Maekawa; F Takaku; H Uchino; T Masaoka; I Amaki; K Kawashima
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Simultaneous administration of granulocyte colony-stimulating factor (Filgrastim) and induction chemotherapy in acute lymphoblastic leukemia. A pilot study.

Authors:  O G Ottmann; A Ganser; M Freund; G Heil; W Hiddemann; W Heit; E Gracien; D Hoelzer
Journal:  Ann Hematol       Date:  1993-10       Impact factor: 3.673

9.  Allogeneic bone marrow transplantation for high risk non-Hodgkin's lymphoma during first complete remission.

Authors:  A P Nademanee; S J Forman; G M Schmidt; P J Bierman; D S Snyder; M R O'Donnell; J A Lipsett; K G Blume
Journal:  Blut       Date:  1987-07

Review 10.  Bone marrow transplantation for acute lymphoblastic leukemia (ALL).

Authors:  H M Lazarus; J M Rowe
Journal:  Med Oncol       Date:  1994       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.